Wednesday, March 04, 2015 2:54:33 PM
I am not sure why they decided on a combo trial (you really should read the posts by Seel, who I followed over here, and also those by TOB) but I am aware they consider Trimesta to be their "legacy" program left over after they had changed management as Kirk had invested.
I agree that Trimesta could be a major boon to many women suffering from MS and hope TEVA or others will be buying or licensing that drug. Also agree the new programs are exciting. Only here since the stock offering in 12/2013 knocked the price down and here for the long term.
BTW, with the handle "black cat" why the non-black cat icon?
I agree that Trimesta could be a major boon to many women suffering from MS and hope TEVA or others will be buying or licensing that drug. Also agree the new programs are exciting. Only here since the stock offering in 12/2013 knocked the price down and here for the long term.
BTW, with the handle "black cat" why the non-black cat icon?
All I say is IMHO and not to be construed as investment advice. I know nothing, as informed frequently by my wife.
Recent TOVX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:41:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:35:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:45:14 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 09:23:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 08:15:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 08:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:10:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/16/2026 09:32:27 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 12:15:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:10:35 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2026 09:35:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:10:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 01:07:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 02:11:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:55:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:54:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:53:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 09:51:09 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/06/2026 08:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2025 01:00:58 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/23/2025 10:04:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2025 10:21:47 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/03/2025 09:00:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/03/2025 05:15:04 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/12/2025 09:11:24 PM
